MS Treatment Market will Reach $11.9 Billion by 2011

NewswireToday - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report showing the growth of MS treatments from $4.4 billion in 2004 to nearly $5.9 billion in 2006

Multiple Sclerosis: Worldwide Market Outlook to 2011” predicts a growth of $6 million by 2011. The report shows the approval of four MS treatment therapies, which generated more than $1 billion in sales each in 2006, contributed to the market’s 15% increase over 2004.

The report predicts that new formulations for existing treatments and new developments, as well as the rising rate of MS across several regions of the world, will support a 15.2% revenue increase over the next five years.

An estimated 2.5 million people worldwide suffer from MS which is a chronic disease that causes significant disability, inflammation, and scarring of the myelin sheaths covering nerves. A decision by the National Institute for Health and Clinical Excellence (NICE) to recommend Tysabri (natalizumab) for a severe form of multiple sclerosis (MS) offers UK patients renewed hope of regaining control over their disease.

NICE’s recommended the new MS drug Tysabri for use in patients with rapidly evolving severe relapse-remitting MS. With no other disease modifying drug recommended by NICE for MS, this recommendation represents a significant milestone for the UK MS market, although it is understood that this will have no impact on the ongoing risk-sharing scheme for other treatments.

The rapid, sustained uptake of Tysabri will result in it becoming the UK MS market leader by 2009, with sales of $29m. With the ongoing restrictions to other marketed drugs and Tysabri’s impressive efficacy profile, this market-leading status is forecast to continue through to 2016...

... Over a two year period, treatment with Tysabri has been shown to result in a 68% relative reduction in clinical relapses and a 54% relative reduction in the risk of sustained disability progression compared with placebo. Subsequently MS sufferers will be able to enjoy a more active and less dependable life.

The report concludes that the disease is undergoing dramatic changes. Regions that were once considered to have low incidence and prevalence of multiple sclerosis are now displaying increases that were not apparent even within the last 10 years.

Multiple Sclerosis: Worldwide Market Outlook to 2011” focuses on currently marketed products in the MS market and includes statistical information for MS worldwide and by selected countries, with special emphasis on the major pharmaceutical markets: the United States, Europe, and Japan.

Full story

* * * * *

I am sad, looking at such an information. The only explanation for that - monster pharmaceutical industry wants to increase profits even more.

They will make everything to persuade MS sufferers that the only option to improve their life - usage of their terribly expensive and often generating serious side effects immunosuppressant drugs.

And they never tell you about existing non-invasive, natural user-friendly alternatives.

I know that - I managed to stop progressing of my initially actively progressing (2 attacks in 4 months) Multiple Sclerosis. Performed MRI scan clearly showed plaques thorough my brain.

At the same time my MS symptoms were growing quite actively. Routine official orthodox treatment - mega doses of methyl-prednisone (Solu-Medrol) - was applied for me. More details can be found in article MS cures story.

As my overall condition after that treatment worsened significantly, I started thinking: 'Something wrong with this chemical etc treatment...' and decided to finish my contacts with orthodox medicine.

Today, over 10 years on permanent MS symptoms remission, my health still slowly improves - completely without these nasty and highly dangerous synthetic drugs.

Final words:


No comments so far

Leave a Reply

Comments are visible after moderation!